Altimmune (NASDAQ:ALT) Stock Price Down 5.3%

Altimmune, Inc. (NASDAQ:ALT)’s stock price fell 5.3% during mid-day trading on Wednesday . The company traded as low as $7.15 and last traded at $7.17. 696,318 shares changed hands during trading, a decline of 87% from the average session volume of 5,372,216 shares. The stock had previously closed at $7.57.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. B. Riley reiterated a “buy” rating and set a $20.00 price target on shares of Altimmune in a research report on Thursday, March 28th. The Goldman Sachs Group began coverage on shares of Altimmune in a research note on Wednesday, January 24th. They set a “neutral” rating and a $13.00 price target for the company. Finally, HC Wainwright decreased their price objective on shares of Altimmune from $15.00 to $12.00 and set a “buy” rating for the company in a research report on Monday, April 1st.

Altimmune Price Performance

The company has a market cap of $514.66 million, a PE ratio of -4.40 and a beta of 0.05. The company has a fifty day moving average price of $9.28 and a 200 day moving average price of $7.52.

Altimmune (NASDAQ:ALT) last issued its earnings results on Wednesday, March 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.02. The business had revenue of $0.04 million during the quarter. Altimmune had a negative return on equity of 44.77% and a negative net margin of 20,780.75%. As a group, sell-side analysts predict that Altimmune, Inc. will post -1.52 EPS for the current fiscal year.

Hedge Funds Weigh In On Altimmune

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. FNY Investment Advisers LLC bought a new position in Altimmune in the fourth quarter worth $35,000. Russell Investments Group Ltd. grew its stake in shares of Altimmune by 1,150.9% in the fourth quarter. Russell Investments Group Ltd. now owns 4,303 shares of the company’s stock worth $48,000 after acquiring an additional 3,959 shares during the last quarter. EWG Elevate Inc. grew its stake in shares of Altimmune by 50.0% in the fourth quarter. EWG Elevate Inc. now owns 15,000 shares of the company’s stock worth $169,000 after acquiring an additional 5,000 shares during the last quarter. Horizon Wealth Management LLC purchased a new stake in shares of Altimmune in the fourth quarter worth $112,000. Finally, Deuterium Capital Management LLC purchased a new stake in shares of Altimmune in the fourth quarter worth $112,000. Institutional investors own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.